prasugrel trial summary

No demonstrated result

suggested Non fatal MI by 24% (not demonstrated)

suggested Revascularization by 33% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
all cause death, MI, stroke	0.96 [0.85 1.08]	p=1.00	0	9326	1	TRILOGY ACS (overall population),
refractory ischemia	no data
cardiovascular events	no data
myocardial infarction (fatal and non fatal)	0.96 [0.83 1.12]	p=1.00	0	9326	1	TRILOGY ACS (overall population),
stroke (fatal and non fatal)	0.90 [0.64 1.27]	p=1.00	0	9326	1	TRILOGY ACS (overall population),
ischemic stroke	no data
Vascular death	0.92 [0.80 1.05]	p=1.00	0	22934	2	TRILOGY ACS (overall population),TRITON-TIMI 38,
Non vascular death	no data
Non fatal MI	0.76 [0.67 0.87]	p=0.04	0	13608	1	TRITON-TIMI 38,
Revascularization	0.67 [0.54 0.82]	p=0.04	0	13608	1	TRITON-TIMI 38,
All cause death	0.94 [0.84 1.06]	p=1.00	0	22934	2	TRILOGY ACS (overall population),TRITON-TIMI 38,
Non fatal stroke	1.01 [0.71 1.45]	p=1.00	0	13608	1	TRITON-TIMI 38,
fatal bleeding	1.82 [0.91 3.65]	p=1.00	0	22934	2	TRILOGY ACS (overall population),TRITON-TIMI 38,
Bleeding	1.30 [1.11 1.51]	p=0.04	0	22934	2	TRILOGY ACS (overall population),TRITON-TIMI 38,
Major bleeding	1.28 [1.04 1.58]	p=0.04	0	22934	2	TRILOGY ACS (overall population),TRITON-TIMI 38,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

Bleeding by 30% (harmful effect)

suggested Non fatal MI by 24% (not demonstrated)

suggested Revascularization by 33% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
all cause death, MI, stroke	0.96 [0.85 1.08]	p=1.00	0	9326	1	TRILOGY ACS (overall population),
refractory ischemia	no data
cardiovascular events	no data
myocardial infarction (fatal and non fatal)	0.96 [0.83 1.12]	p=1.00	0	9326	1	TRILOGY ACS (overall population),
stroke (fatal and non fatal)	0.90 [0.64 1.27]	p=1.00	0	9326	1	TRILOGY ACS (overall population),
ischemic stroke	no data
Vascular death	0.92 [0.80 1.05]	p=1.00	0	22934	2	TRILOGY ACS (overall population),TRITON-TIMI 38,
Non vascular death	no data
Non fatal MI	0.76 [0.67 0.87]	p=0.04	0	13608	1	TRITON-TIMI 38,
Revascularization	0.67 [0.54 0.82]	p=0.04	0	13608	1	TRITON-TIMI 38,
All cause death	0.94 [0.84 1.06]	p=1.00	0	22934	2	TRILOGY ACS (overall population),TRITON-TIMI 38,
Non fatal stroke	1.01 [0.71 1.45]	p=1.00	0	13608	1	TRITON-TIMI 38,
fatal bleeding	1.82 [0.91 3.65]	p=1.00	0	22934	2	TRILOGY ACS (overall population),TRITON-TIMI 38,
Bleeding	1.30 [1.11 1.51]	p=0.04	0	22934	2	TRILOGY ACS (overall population),TRITON-TIMI 38,
Major bleeding	1.28 [1.04 1.58]	p=0.04	0	22934	2	TRILOGY ACS (overall population),TRITON-TIMI 38,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Patients not initialy planned for PCI: 1 trials - TRILOGY ACS (overall population)

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
all cause death, MI, stroke	0.96 [0.85 1.08]	p=1.00	0	9326	1	TRILOGY ACS (overall population),
refractory ischemia	no data
cardiovascular events	no data
myocardial infarction (fatal and non fatal)	0.96 [0.83 1.12]	p=1.00	0	9326	1	TRILOGY ACS (overall population),
stroke (fatal and non fatal)	0.90 [0.64 1.27]	p=1.00	0	9326	1	TRILOGY ACS (overall population),
ischemic stroke	no data
Vascular death	0.93 [0.79 1.10]	p=1.00	0	9326	1	TRILOGY ACS (overall population),
Non vascular death	no data
Non fatal MI	no data
Revascularization	no data
All cause death	0.94 [0.81 1.09]	p=1.00	0	9326	1	TRILOGY ACS (overall population),
Non fatal stroke	no data
fatal bleeding	0.78 [0.29 2.09]	p=1.00	0	9326	1	TRILOGY ACS (overall population),
Bleeding	1.26 [0.93 1.70]	p=1.00	0	9326	1	TRILOGY ACS (overall population),
Major bleeding	1.21 [0.82 1.78]	p=1.00	0	9326	1	TRILOGY ACS (overall population),

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Patients with scheduled percutaneous coronary intervention : 1 trials - TRITON-TIMI 38

No demonstrated result

Bleeding by 31% (harmful effect)

suggested Non fatal MI by 24% (not demonstrated)

suggested Revascularization by 33% (not demonstrated)

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	no data
Cardiovascular death	no data
myocardial infarction (fatal and non fatal)	no data
stroke (fatal and non fatal)	no data
MACE	no data
All cause death	no data
Major bleeding	no data
net benefit	no data
stent thrombosis	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Patients with high residual platelet activity on clopidogrel: 1 trials - TRIGGER-PCI

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	no data
Cardiovascular death	no data
myocardial infarction (fatal and non fatal)	no data
stroke (fatal and non fatal)	no data
MACE	no data
All cause death	no data
Major bleeding	no data
net benefit	no data
stent thrombosis	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Prasugrel antiplatelets drug